Search

Your search keyword '"Kreuzer, K. A."' showing total 4 results
Start Over Author "Kreuzer, K. A." Topic flow cytometry
4 results on '"Kreuzer, K. A."'

1. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Author

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, and Ghia P

Subjects
Adolescent, Adult, Combined Modality Therapy, Europe, Female, Follow-Up Studies, Humans, Immunophenotyping, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Neoplasm Staging, Neoplasm, Residual genetics, Neoplasm, Residual metabolism, Prognosis, Young Adult, Antigens, CD metabolism, Flow Cytometry standards, High-Throughput Nucleotide Sequencing methods, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Neoplasm, Residual diagnosis
Abstract

In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.

Published
2016
Full Text
View/download PDF

2. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry:An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

Author

Rawstron, AC, Kreuzer, K-A, Soosapilla, A, Spacek, M, Stehlikova, O, Gambell, P, McIver-Brown, N, Villamor, N, Psarra, K, Arroz, M, Milani, R, de la Serna, J, Cedena, MT, Jaksic, O, Nomdedeu, J, Moreno, C, Rigolin, GM, Cuneo, A, Johansen, P, Johnsen, HE, Rosenquist, R, Niemann, CU, Kern, W, Westerman, D, Trneny, M, Mulligan, S, Doubek, M, Pospisilova, S, Hillmen, P, Oscier, D, Hallek, M, Ghia, P, Montserrat, E, Rawstron, Andy C., Kreuzer, Karl-Anton, Soosapilla, Asha, Spacek, Martin, Stehlikova, Olga, Gambell, Peter, McIver-Brown, Neil, Villamor, Neu, Psarra, Katherina, Arroz, Maria, Milani, Raffaella, de la Serna, Javier, Cedena, M. Teresa, Jaksic, Ozren, Nomdedeu, Josep, Moreno, Carol, Rigolin, Gian Matteo, Cuneo, Antonio, Johansen, Preben, Johnsen, Hans E., Rosenquist, Richard, Niemann, Carsten Utoft, Kern, Wolfgang, Westerman, David, Trneny, Marek, Mulligan, Stephen, Doubek, Michael, Pospisilova, Sarka, Hillmen, Peter, Oscier, David, Hallek, Michael, Ghia, Paolo, and Montserrat, Emili

Subjects
chronic lymphocytic leukemia, diagnosis, flow cytometry, 2734, Histology, Cell Biology, Clinical Laboratory Medicine, Reproducibility of Results, Pilot Projects, Original Articles, Leukemia, Lymphocytic, Chronic, B-Cell, NO, Immunophenotyping, diagnosi, Klinisk laboratoriemedicin, immune system diseases, hemic and lymphatic diseases, Biomarkers, Tumor, Humans, Original Article, Retrospective Studies
Abstract

The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as “required” or “recommended” for CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to validate “required” markers using normal peripheral blood was developed. Responses were received from 150 participants with a diagnostic workload >20 CLL cases per week in 23/150 (15%), 5–20 in 82/150 (55%), and 97% concordance with current approaches. A pilot study to validate staining quality was completed in 11 centers. Markers considered as “required” for the diagnosis of CLL by the participants in this study (CD19, CD5, CD20, CD23, Kappa, and Lambda) are consistent with current diagnostic criteria and practice. Importantly, a reproducible approach to validate and apply these markers in individual laboratories has been identified. Finally, a consensus “recommended” panel of markers to refine diagnosis in borderline cases (CD43, CD79b, CD81, CD200, CD10, and ROR1) has been defined and will be prospectively evaluated. © 2017 International Clinical Cytometry Society.

Published
2018
Full Text
View/download PDF

3. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

Author

Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, RM, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, AP, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, JL, Stetler-Stevenson, M, Yuan, C, Broome, HE, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, CM, Emerson, R, Robins, HS, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, TJ, Wierda, WG, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P, CLL, ERIC European Res Initiative, Rawstron, Ac, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, Ka, Liptrot, S, O'Brien, D, de Tute, Rm, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, Ap, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, Jl, Stetler Stevenson, M, Yuan, C, Broome, He, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, Cm, Emerson, R, Robins, H, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, Tj, Wierda, Wg, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, PAOLO PROSPERO, AII - Amsterdam institute for Infection and Immunity, CCA -Cancer Center Amsterdam, and Clinical Haematology

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Neoplasm, Residual, Lymphoma, Chronic lymphocytic leukemia, 0302 clinical medicine, Immunophenotyping, immune system diseases, hemic and lymphatic diseases, Chronic, Cancer, CD20, Hematology, Leukemia, biology, High-Throughput Nucleotide Sequencing, Prognosis, Flow Cytometry, Combined Modality Therapy, Lymphocytic, 3. Good health, CD, Europe, 030220 oncology & carcinogenesis, Residual, Original Article, Female, Adult, medicine.medical_specialty, Adolescent, Clinical Sciences, Oncology and Carcinogenesis, Immunology, 03 medical and health sciences, Young Adult, Rare Diseases, Antigens, CD, Internal medicine, medicine, Humans, Antigens, Neoplasm Staging, business.industry, B-Cell, CD79B, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Minimal residual disease, Orphan Drug, 030104 developmental biology, biology.protein, Neoplasm, CD5, business, Follow-Up Studies
Abstract

In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.

Published
2016

4. PILOT STUDY TO ASSESS REAGENT AND INSTRUMENT QUALITY FOR REPRODUCIBLE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: AN ESCCA AND ERIC HARMONISATION PROJECT

Author

Rawstron, A., Kreuzer, K. A., Soosapilla, A., Spacek, M., Stehlikova, O., Gambell, P., Mciver-Brown, N., Psarra, K., Arroz, M., Milani, R., La Serna, J., Teresa, C. M., Jaksic, O., Nomdedeu, J. F., Moreno, C., Rigolin, G. M., Cuneo, A., Johansen, P., Johnsen, H. E., Rosenquist, R., Niemann, C. U., Wolfgang Kern, Westerman, D. A., Trneny, M., Mulligan, S. P., Doubek, M., Pospisilova, S., Hillmen, P., Oscier, D. G., Hallek, M., Ghia, P., and Montserrat, E.

Subjects
CLL, flow cytometry, flow cytometry, CLL, NO

Catalog

Books, media, physical & digital resources
See catalog results